Can a Janus kinase (JAK) inhibitor be used to treat colitis in a patient with autoimmune hepatitis (AIH)?

JAK Inhibitors for Colitis in Patients with Autoimmune Hepatitis

JAK inhibitors should generally be avoided in patients with autoimmune hepatitis (AIH) who have colitis, as there is insufficient evidence for their safety in this specific population and significant theoretical concerns about hepatotoxicity.

Key Considerations

The Core Problem

The question presents a challenging clinical scenario where two autoimmune conditions intersect. While JAK inhibitors have proven efficacy for ulcerative colitis, their use in patients with pre-existing AIH raises critical safety concerns that currently lack adequate evidence.

Evidence for JAK Inhibitors in Colitis

For standard ulcerative colitis management:

• Tofacitinib, upadacitinib, and filgotinib are approved for moderate-to-severe UC 1, 2
• Tofacitinib achieves clinical remission in 18.5-16.6% at week 8 (vs 3.6-8.2% placebo) 3
• Upadacitinib demonstrates superior efficacy with 29.1% clinical remission (vs 3.7% placebo) 1
• In acute severe UC, tofacitinib shows 82% colectomy-free rates and upadacitinib 79% 4

The Critical Safety Gap in AIH

The 2025 British Society of Gastroenterology AIH guidelines make no mention of JAK inhibitors 5, which is telling—these agents are not part of the established AIH treatment paradigm. The standard AIH treatment remains corticosteroids plus azathioprine 5.

Hepatotoxicity concerns:

• JAK inhibitors can cause hepatotoxicity, with monitoring of liver enzymes required 6
• The 2021 consensus statement on JAK inhibitors recommends dose adjustments for "significantly impaired hepatic function" 6
• In patients with pre-existing liver disease, the risk-benefit calculation fundamentally changes

Special Context: Immune Checkpoint Inhibitor-Related Disease

If this colitis is immune checkpoint inhibitor (ICI)-related rather than primary IBD:

• The 2021 ASCO guidelines mention JAK inhibitor tofacitinib as a last-resort option for ICI-related colitis refractory to steroids, infliximab, vedolizumab, fecal microbiota transplant, and ustekinumab 7
• However, infliximab is contraindicated for hepatic immune-related adverse events 7
• One case report describes successful use of ruxolitinib for steroid-refractory ICI-related hepatitis after tocilizumab failure 8
• A 2025 prospective study showed JAK inhibitors achieved 70.8% response rates in life-threatening irAEs, including hepatitis (n=3) 9

Clinical Algorithm

Step 1: Clarify the Type of Colitis

• If ICI-related colitis with concurrent ICI-hepatitis: JAK inhibitors may be considered as salvage therapy after multiple other agents have failed, given that infliximab is contraindicated for hepatic irAEs 7
• If primary IBD (UC or CD) with pre-existing AIH: Avoid JAK inhibitors

Step 2: For ICI-Related Disease Only

If considering JAK inhibitors in the ICI context:

• Ensure failure of corticosteroids, vedolizumab, and ustekinumab first 7
• Use systemic immunosuppressants (prednisone + mycophenolate) that work for both conditions 7
• Monitor liver enzymes intensively (1-2 times weekly minimum)
• Consider multidisciplinary consultation with hepatology and oncology

Step 3: For Primary IBD with AIH

Prioritize alternative advanced therapies:

• Vedolizumab is gut-selective and may be safer in hepatic disease 1
• Infliximab (if no contraindications) has extensive safety data
• Ustekinumab or IL-23 inhibitors (risankizumab, guselkumab) as alternatives 1

Step 4: Absolute Requirements if JAK Inhibitor Use is Unavoidable

• Baseline and frequent liver function monitoring (AST, ALT, bilirubin, alkaline phosphatase)
• Ensure AIH is in remission with stable liver enzymes
• Close hepatology co-management
• Patient counseling on hepatotoxicity risk
• Consider lower doses initially

Critical Pitfalls

1. Do not assume IBD safety data applies to AIH patients - clinical trials systematically excluded patients with significant liver disease
2. Do not use JAK inhibitors as first-line therapy when safer alternatives exist for colitis in AIH patients
3. Do not overlook drug-drug interactions - many AIH patients are on azathioprine, which has its own hepatotoxicity profile
4. Do not forget HBV screening - required before any immunosuppression, including JAK inhibitors 10

The Bottom Line

In patients with AIH and colitis, exhaust all other therapeutic options before considering JAK inhibitors. The only scenario where JAK inhibitors might be justified is in ICI-related disease affecting both liver and gut, where they serve as a last-resort salvage therapy after multiple conventional immunosuppressants have failed 7, 9. For primary IBD with AIH, vedolizumab or other biologics represent safer choices with established efficacy 1.